Fagan Associates Inc. Purchases 17,292 Shares of Gilead Sciences, Inc. $GILD

Fagan Associates Inc. purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 17,292 shares of the biopharmaceutical company’s stock, valued at approximately $2,577,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Forvis Mazars Wealth Advisors LLC lifted its holdings in shares of Gilead Sciences by 7.9% in the 3rd quarter. Forvis Mazars Wealth Advisors LLC now owns 2,540 shares of the biopharmaceutical company’s stock valued at $379,000 after purchasing an additional 187 shares during the last quarter. Contravisory Investment Management Inc. grew its stake in Gilead Sciences by 4.6% during the 3rd quarter. Contravisory Investment Management Inc. now owns 6,000 shares of the biopharmaceutical company’s stock worth $894,000 after buying an additional 263 shares during the last quarter. Sax Wealth Advisors LLC grew its stake in Gilead Sciences by 45.7% during the 3rd quarter. Sax Wealth Advisors LLC now owns 3,771 shares of the biopharmaceutical company’s stock worth $562,000 after buying an additional 1,183 shares during the last quarter. Fragasso Financial Advisors Inc increased its position in Gilead Sciences by 135.4% during the third quarter. Fragasso Financial Advisors Inc now owns 7,035 shares of the biopharmaceutical company’s stock worth $1,063,000 after buying an additional 4,046 shares during the period. Finally, HF Advisory Group LLC increased its position in Gilead Sciences by 8.6% during the third quarter. HF Advisory Group LLC now owns 25,492 shares of the biopharmaceutical company’s stock worth $3,800,000 after buying an additional 2,029 shares during the period. 83.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on GILD. Needham & Company LLC reiterated a “buy” rating and issued a $170.00 price objective on shares of Gilead Sciences in a research note on Wednesday, August 5th. Wall Street Zen upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Saturday, September 19th. Barclays cut their target price on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 29th. Zacks Research cut shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 29th. Finally, Royal Bank Of Canada upped their price target on shares of Gilead Sciences from $123.00 to $126.00 and gave the company a “sector perform” rating in a research report on Thursday, October 8th. Twenty-three analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $159.33.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD traded down $2.51 during midday trading on Tuesday, reaching $147.92. 5,557,687 shares of the company were exchanged, compared to its average volume of 6,816,672. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03. Gilead Sciences, Inc. has a 1 year low of $114.02 and a 1 year high of $157.29. The stock has a fifty day simple moving average of $145.77 and a 200 day simple moving average of $136.87. The stock has a market cap of $183.41 billion, a P/E ratio of -55.40 and a beta of 0.31.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, beating the consensus estimate of ($7.25) by $0.50. The firm had revenue of $7.80 billion for the quarter, compared to analysts’ expectations of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%. The firm’s revenue for the quarter was up 10.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.01 EPS. On average, research analysts forecast that Gilead Sciences, Inc. will post -0.47 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th were paid a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.2%. The ex-dividend date was Tuesday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is -122.85%.

Insider Buying and Selling

In other news, CEO Daniel O’Day sold 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $148.64, for a total transaction of $2,229,600.00. Following the completion of the sale, the chief executive officer owned 577,133 shares in the company, valued at $85,785,049.12. This represents a 2.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $145.29, for a total value of $435,870.00. Following the sale, the chief financial officer directly owned 164,096 shares of the company’s stock, valued at approximately $23,841,507.84. This represents a 1.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 105,000 shares of company stock worth $14,940,540. 0.30% of the stock is currently owned by insiders.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Analysts remain bullish on Gilead, highlighting the company among attractive healthcare stocks. The positive view reflects Gilead’s HIV, liver-disease and oncology franchises, as well as its longer-term growth prospects. Analysts Are Bullish on These Healthcare Stocks: BioNTech SE (BNTX), Gilead Sciences (GILD)
• Positive Sentiment: Bank of America said survey results support a favorable long-term outlook for Yeztugo, Gilead’s HIV-prevention drug. Strong adoption potential could provide an additional growth driver for the company’s HIV portfolio. Gilead Sciences’ Yeztugo Survey Supports Long-Term Growth Outlook, BofA Says
• Positive Sentiment: Erste Group Bank modestly raised its FY2027 EPS forecast for Gilead to $9.90 from $9.88, signaling confidence in the company’s future profitability. Erste Group Bank Raises Gilead Sciences EPS Estimate
• Neutral Sentiment: Recent comparisons with GRAIL and Vertex Pharmaceuticals provide valuation and operating-context analysis but do not identify a specific new catalyst for GILD. Contrasting GRAIL and Gilead Sciences Gilead Sciences versus Vertex Pharmaceuticals
• Negative Sentiment: Gilead’s upcoming third-quarter earnings report is expected to show a double-digit year-over-year EPS decline. That forecast is weighing on sentiment despite optimism about the company’s longer-term pipeline and product growth. Earnings Preview: What to Expect From Gilead Sciences’ Report

About Gilead Sciences

Gilead Sciences, Inc (NASDAQ: GILD) is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. Its research and commercial activities focus primarily on virology, including HIV, hepatitis B and hepatitis C, as well as oncology, inflammation and other areas of significant unmet medical need.

Gilead’s portfolio includes HIV treatments such as Biktarvy, Descovy, Genvoya and Sunlenca; hepatitis therapies including Epclusa, Harvoni and Vemlidy; and Veklury (remdesivir), an antiviral used to treat COVID-19 in certain patients.